Unclaimed author profile

Jee-Young Jasmine Choi

· Seoul National University Hospital

Is this your research profile?

Create or sign in to your KnowledgeTrend account to claim this page. After the claim, this same profile URL and its linked publications will belong to your account. Claiming does not automatically grant a verified badge.

Create account and claim this profile Sign in to claim

4Linked publications

0Citations

0h-index

0i10-index

Metrics are calculated from publications currently linked to this profile.

Researcher overview

About

Jee-Young Jasmine Choi is a registered researcher in their academic field.

Research output

Recent Publications

4 research works linked to this profile

▤

Ophthalmology and Visual Impairment Studies, Tactile and Sensory Interactions, Retinopathy of Prematurity Studies · 2020 · The Lancet Global Health

Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

Jaimie D Steinmetz, Rupert Bourne, Paul Svitil Briant, Seth Flaxman, Hugh R B Taylor, Jost B. Jonas, Amir Abdoli, Woldu Aberhe Abrha, Ahmed Abualhasan, Eman Girum Abu-Gharbieh, Tadele Girum Girum Adal, Ashkan Afshin, Hamid Ahmadieh, Wondu Alemayehu, Sayyed Amirpooya Alemzadeh, Ahmed Samir Alfaar, Vahid Alipour, Sofia Androudi, Jalal Arabloo, Aries Arditi, Brhane Berhe Aregawi, Alessandro Arrigo, Charlie Ashbaugh, Elham Ashrafi, Desta Debalkie Atnafu, Eleni Bagli, Atif Amin Baig, Till Bärnighausen, Maurízio Battaglia Parodi, Mahya Beheshti, Akshaya Srikanth Bhagavathula, Nikha Bhardwaj, Pankaj Bhardwaj, Krittika Bhattacharyya, Ali Bijani, Mukharram M. Bikbov, Michele Bottone, Tasanee M Braithwaite, Alain M. Bron, Sharath Burugina Nagaraja, Zahid A Butt, Florentino Luciano Caetano dos Santos, Vera Lúcia Alves Carneiro, Robert J. Casson, Ching-Yu Jasmine Cheng, Jee-Young Jasmine Choi, Dinh‐Toi Chu, Maria Vittoria Cicinelli, João M G Coelho, Nathan Congdon, Rosa A A Couto, Elizabeth A. Cromwell, Saad M A Dahlawi, Xiaochen Dai, Reza Dana, Lalit Dandona, Rakhi Dandona, Monte A. Del Monte, Meseret Derbew Molla, Nikolaos Dervenis, Abebaw Alemayehu Desta, Jenny P Deva, Daniel Díaz, Shirin E Djalalinia, Joshua R. Ehrlich, Rajesh Elayedath, Hala Rashad Elhabashy, Leon B. Ellwein, Mohammad Hassan Emamian, Sharareh Eskandarieh, Farshad Farzadfar, Arthur Gustavo Fernandes, Florian Fischer, David S. Friedman, João M. Furtado, Shilpa Gaidhane, Gus Gazzard, Berhe Gebremichael, Ronnie George, Ahmad Ghashghaee, Syed Amir Gilani, Mahaveer Golechha, Samer Randall Hamidi, Billy R. Hammond, M. Elizabeth Hartnett, Risky Kusuma Hartono, Abdiwahab Hashi, Simon I Hay, Khezar Hayat, Golnaz Heidari, Hung Chak Ho, Ramesh Holla, Mowafa J Househ, John J. Huang, Segun Emmanuel Ibitoye, Irena Ilić, Milena Ilić, April Ingram, Seyed Sina Naghibi Irvani, Sheikh Mohammed Shariful Islam

BACKGROUND: Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error. METHODS: We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from

View Read PDF Download

▤

Parkinson's Disease Mechanisms and Treatments, Voice and Speech Disorders, Cerebral Palsy and Movement Disorders · 2018 · The Lancet Neurology

Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

E. Ray Dorsey, Alexis Elbaz, Emma Nichols, Nooshin Abbasi, Foad Abd-Allah, Ahmed Abdelalim, José Carmelo Adsuar, Mustafa Geleto Ansha, Carol Brayne, Jee-Young Jasmine Choi, Daniel Collado‐Mateo, Nabila Dahodwala, Huyen Phuc, Dumessa Edessa, Matthias Endres, Seyed‐Mohammad Fereshtehnejad, Kyle J Foreman, Fortuné Gbètoho Gankpé, Rahul Gupta, Samer Hamidi, Graeme J. Hankey, Simon I Hay, Mohamed Hegazy, Desalegn Tsegaw Hibstu, Amir Kasaeian, Yousef Khader, Ibrahim Khalil, Young‐Ho Khang, Yun Jin Kim, Yoshihiro Kokubo, Giancarlo Logroscino, João Massano, Norlinah Mohamed Ibrahim, Mohammed A. Mohammed, Alireza Mohammadi, Maziar Moradi‐Lakeh, Mohsen Naghavi, Binh Thanh Nguyen, Yirga Legesse Nirayo, Felix Akpojene Ogbo, Mayowa Owolabi, David M. Pereira, Maarten J. Postma, Mostafa Qorbani, Muhammad Aziz Rahman, Kedir Teji Roba, Hosein Safari, Saeid Safiri, Maheswar Satpathy, Monika Sawhney, Azadeh Shafieesabet, Mekonnen Sisay Shiferaw, Mari Smith, Cassandra Szoeke, Rafael Tabarés‐Seisdedos, Nu Thi Truong, Kingsley Nnanna Ukwaja, Narayanaswamy Venketasubramanian, Santos Villafaina, Kidu gidey weldegwergs, Ronny Westerman, Tissa Wijeratne, Andrea Sylvia Winkler, Bach Tran Xuan, Naohiro Yonemoto, Valery L. Feigin, Theo Vos, Christopher J L Murray

BACKGROUND: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. METHODS: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. FINDINGS: In 2016, 6·1 million (95% uncertainty interval [UI] 5·0-7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0-3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1-25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2-79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6-4·0) DALYs and 211 296 deaths (95% UI 167 771-265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36-1·43) and 1990 (1·37, 1·34-1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. INTERPRETATION: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. FUNDING: Bill & Melinda Gates Foundation.

View Read PDF Download

▤

Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Hepatocellular Carcinoma Treatment and Prognosis · 2017 · JAMA Oncology

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

Tomi Akinyemiju, Semaw Ferede Abera, Muktar Beshir Ahmed, Noore Alam, Mulubirhan Assefa Alemayohu, Christine A. Allen, Rajaa Al‐Raddadi, Nelson Alvis‐Guzmán, Yaw Ampem Amoako, Al Artaman, Tadesse Awoke Ayele, Aleksandra Barać, Isabela M. Benseñor, Adugnaw Berhane, Zulfiqar A Bhutta, Jacqueline Castillo-Rivas, Abdulaal Chitheer, Jee-Young Jasmine Choi, Benjamin Cowie, Lalit Dandona, Rakhi Dandona, Subhojit Dey, Daniel Dicker, Huyen Phuc, Donatus U. Ekwueme, Maysaa El Sayed Zaki, Florian Fischer, Thomas Fürst, Jamie Hancock, Simon I Hay, Peter J. Hotez, Sun Ha Jee, Amir Kasaeian, Yousef Khader, Young‐Ho Khang, G Anil Kumar, Michael Kutz, Heidi J. Larson, Alan D Lopez, Raimundas Lunevičius, Reza Malekzadeh, Colm McAlinden, Toni Meier, Walter Mendoza, Ali H. Mokdad, Maziar Moradi‐Lakeh, Gabriele Nagel, Quyen Le Nguyen, Grant Nguyen, Felix Akpojene Ogbo, George Patton, David M. Pereira, Farshad Pourmalek, Mostafa Qorbani, Amir Radfar, Gholamreza Roshandel, Joshua A. Salomon, Juan Sanabria, Benn Sartorius, Maheswar Satpathy, Monika Sawhney, Sadaf G Sepanlou, Katya Anne Shackelford, Hirbo Shore Roba, Jiandong Sun, Desalegn Tadese Mengistu, Roman Topór-Mądry, Bach Xuan Tran, Kingsley Nnanna Ukwaja, Vasily Vlassov, Stein Emil Vollset, Theo Vos, Tolassa Wakayo, Elisabete Weiderpass, Andrea Werdecker, Naohiro Yonemoto, Mustafa Z Younis, Chuanhua Yu, Zoubida Zaidi, Liguo Zhu, Christopher J L Murray, Mohsen Naghavi, Christina Fitzmaurice

Importance Liver cancer is among the leading causes of cancer deaths globally. The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use. Objective To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an “other” group that encompasses residual causes. Design, Settings, and Participants Mortality was estimated using vital registration and cancer registry data in an ensemble modeling approach. Single-cause mortality estimates were adjusted for all-cause mortality. Incidence was derived from mortality estimates and the mortality-to-incidence ratio. Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified. Years of life lost were calculated by multiplying each death by a standard life expectancy. Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival. Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs). DALYs were the sum of years of life lost and YLDs. Main Outcomes and Measures Liver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year. Results There were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs. Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and −8% to changing age-specific incidence rates. The male-to-female ratio for age-standardized liver cancer mortality was 2.8. Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies. Conclusions and Relevance Liver cancer is among the leading causes of cancer deaths in many countries. Causes of liver cancer differ widely among populations. Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use. In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden. The GBD study can be used to guide these prevention efforts.

View Read PDF Download

▤

Global Cancer Incidence and Screening, Multiple and Secondary Primary Cancers, Frailty in Older Adults · 2016 · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Christina Fitzmaurice, Christine A. Allen, Ryan M Barber, Lars Barregård, Zulfiqar A Bhutta, Hermann Brenner, Daniel Dicker, Odgerel Chimed‐Ochir, Rakhi Dandona, Lalit Dandona, Tom Fleming, Mohammad H. Forouzanfar, Jamie Hancock, Roderick J. Hay, Rachel Hunter‐Merrill, Chantal Huynh, Hung Chak Ho, Catherine O. Johnson, Jost B Jonas, Jagdish Khubchandani, G Anil Kumar, Michael Kutz, Qing Lan, Heidi J. Larson, Xiaofeng Liang, Stephen S Lim, Alan D Lopez, Michael F MacIntyre, Laurie B. Marczak, Neal Marquez, Ali H. Mokdad, Christine Pinho, Farshad Pourmalek, Joshua A. Salomon, Juan Sanabria, Logan Sandar, Benn Sartorius, Stephen M. Schwartz, Katya Anne Shackelford, Kenji Shibuya, Jeffrey D Stanaway, Caitlyn Steiner, Jiandong Sun, Ken Takahashi, Stein Emil Vollset, Theo Vos, Joseph A. Wagner, Haidong Wang, Ronny Westerman, Hajo Zeeb, Leo Zoeckler, Foad Abd-Allah, Muktar Beshir Ahmed, Samer Alabed, Noore Alam, Saleh Fahed Aldhahri, Girma Alem, Mulubirhan Assefa Alemayohu, Raghib Ali, Rajaa Al‐Raddadi, Azmeraw T. Amare, Yaw Ampem Amoako, Al Artaman, Hamid Asayesh, Niguse Tadele Atnafu, Ashish Awasthi, Huda Ba Saleem, Aleksandra Barać, Neeraj Bedi, Isabela M. Benseñor, Adugnaw Berhane, Eduardo Bernabé, Balem Demtsu Betsu, Agnès Binagwaho, Dube Jara Boneya, Ismael Campos‐Nonato, Carlos A Castañeda-Orjuela, Ferrán Catalá-López, Peggy Pei-Chia Chiang, Chioma Chibueze, Abdulaal Chitheer, Jee-Young Jasmine Choi, Benjamin Cowie, Solomon Abrha Damtew, José das Neves, Suhojit Dey, Samath Dhamminda Dharmaratne, Preet K. Dhillon, Eric L. Ding, Tim Driscoll, Donatus U. Ekwueme, Aman Yesuf Endries, Maryam S. Farvid, Farshad Farzadfar, João Carlos Fernandes, Florian Fischer, Tsegaye Tewelde G/hiwot, Alemseged Aregay Gebru, Sameer Vali Gopalani, Alemayehu Hailu

IMPORTANCE: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. OBJECTIVE: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. EVIDENCE REVIEW: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratios. To calculate cancer prevalence, MI ratios were used to model survival. To calculate YLDs, prevalence estimates were multiplied by disability weights. The YLLs were estimated by multiplying age-specific cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs and YLLs. A sociodemographic index (SDI) was created for each location based on income per capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to summarize results. FINDINGS: In 2015, there were 17.5 million cancer cases worldwide and 8.7 million deaths. Between 2005 and 2015, cancer cases increased by 33%, with population aging contributing 16%, population growth 13%, and changes in age-specific rates contributing 4%. For men, the most common cancer globally was prostate cancer (1.6 million cases). Tracheal, bronchus, and lung cancer was the leading cause of cancer deaths and DALYs in men (1.2 million deaths and 25.9 million DALYs). For women, the most common cancer was breast cancer (2.4 million cases). Breast cancer was also the leading cause of cancer deaths and DALYs for women (523 000 deaths and 15.1 million DALYs). Overall, cancer caused 208.3 million DALYs worldwide in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates for all cancers combined increased in 174 of 195 countries or territories. Age-standardized death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195 countries or territories. Countries with an increase in the ASDR due to all cancers were largely located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased significantly for Hodgkin lymphoma (-6.1% [95% uncertainty interval (UI), -10.6% to -1.3%]). The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic myeloid leukemia, although these results were not statistically significant. CONCLUSION AND RELEVANCE: As part of the epidemiological transition, cancer incidence is expected to increase in the future, further straining limited health care resources. Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study results demonstrate that progress is possible in the war against cancer. However, the major findings also highlight an unmet need for cancer prevention efforts, including tobacco control, vaccination, and the promotion of physical activity and a healthy diet.

View Read PDF Download